STAAR Surgical Company is highlighted as one of the top small-cap stocks to invest in before the next breakout. Morgan Stanley resumed coverage of STAA with an Underweight rating and $13 price target after the termination of its merger agreement with Alcon. Analysts question STAA’s standalone valuation post-merger, with Canaccord Genuity lowering its price target to $22 and maintaining a Hold rating. STAAR Surgical Company is a U.S. ophthalmic medical device firm known for its implantable lenses. While STAA shows investment potential, some believe AI stocks offer greater upside with less risk. No disclosures were reported.

Read more at Yahoo Finance: Analysts Question STAAR Surgical Company (STAA)’s Post-Merger Standalone Valuation